SG11201811393WA - Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer - Google Patents
Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancerInfo
- Publication number
- SG11201811393WA SG11201811393WA SG11201811393WA SG11201811393WA SG11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- cancer
- ucsf
- san francisco
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354449P | 2016-06-24 | 2016-06-24 | |
| US201662426095P | 2016-11-23 | 2016-11-23 | |
| PCT/US2017/039119 WO2017223516A1 (en) | 2016-06-24 | 2017-06-23 | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811393WA true SG11201811393WA (en) | 2019-01-30 |
Family
ID=59297390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811393WA SG11201811393WA (en) | 2016-06-24 | 2017-06-23 | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11072600B2 (fi) |
| EP (1) | EP3475272B1 (fi) |
| JP (2) | JP7033588B2 (fi) |
| KR (1) | KR102494294B1 (fi) |
| CN (1) | CN109843874B (fi) |
| AU (1) | AU2017280334C1 (fi) |
| BR (1) | BR112018076821A2 (fi) |
| CA (1) | CA3029004A1 (fi) |
| ES (1) | ES2964531T3 (fi) |
| IL (1) | IL263917B (fi) |
| MX (2) | MX2018015893A (fi) |
| PL (1) | PL3475272T3 (fi) |
| PT (1) | PT3475272T (fi) |
| SG (1) | SG11201811393WA (fi) |
| WO (1) | WO2017223516A1 (fi) |
| ZA (2) | ZA201808562B (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562886B2 (en) | 2015-05-21 | 2020-02-18 | The Regents Of The University Of California | Anti-cancer compounds |
| CN108884054B (zh) * | 2015-11-30 | 2022-08-02 | 儿童医学中心公司 | 用于治疗增殖性疾病的化合物 |
| AU2017280334C1 (en) | 2016-06-24 | 2022-10-20 | AtlasMedx, Inc | Phthalazine derivatives as inhibitors of PARP1, PARP2 and/or tubulin useful for the treatment of cancer |
| US11590130B2 (en) | 2018-04-05 | 2023-02-28 | Noviga Research Ab | Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer |
| CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401171A (en) | 1966-03-11 | 1968-09-10 | Smithkline Corp | 2-amidobenzimidazoles |
| SU1019810A1 (ru) | 1981-07-28 | 1991-04-07 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью |
| SU1218649A1 (ru) | 1984-09-19 | 1991-04-30 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы |
| AU2720199A (en) | 1998-02-03 | 1999-08-23 | Boehringer Ingelheim Pharma Kg | Five-membered, benzo-condensed heterocycles used as antithrombotic agents |
| WO2000044726A1 (fr) | 1999-01-26 | 2000-08-03 | Ono Pharmaceutical Co., Ltd. | Derives 2h-phthalazine-1-one et medicaments renfermant ces derives comme principe actif |
| DE19907813A1 (de) | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| EP1751124A4 (en) | 2004-05-07 | 2010-04-14 | Exelixis Inc | RAF MODULATORS AND METHODS OF USE |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| CN101291928A (zh) * | 2005-10-19 | 2008-10-22 | 库多斯药物有限公司 | 4-杂芳甲基取代的酞嗪酮衍生物 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| SI2271626T1 (sl) * | 2008-03-27 | 2015-03-31 | Janssen Pharmaceutica, N.V. | Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina |
| EP2529235B1 (en) | 2010-01-29 | 2019-03-06 | Metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CA2875025C (en) | 2011-05-31 | 2021-08-03 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| KR101546743B1 (ko) * | 2012-01-16 | 2015-08-24 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| EA201591239A1 (ru) * | 2012-12-31 | 2015-10-30 | Кадила Хелзкэр Лимитед | Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1 |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| AU2017280334C1 (en) * | 2016-06-24 | 2022-10-20 | AtlasMedx, Inc | Phthalazine derivatives as inhibitors of PARP1, PARP2 and/or tubulin useful for the treatment of cancer |
-
2017
- 2017-06-23 AU AU2017280334A patent/AU2017280334C1/en active Active
- 2017-06-23 CN CN201780051422.3A patent/CN109843874B/zh active Active
- 2017-06-23 MX MX2018015893A patent/MX2018015893A/es unknown
- 2017-06-23 SG SG11201811393WA patent/SG11201811393WA/en unknown
- 2017-06-23 JP JP2019519615A patent/JP7033588B2/ja active Active
- 2017-06-23 IL IL263917A patent/IL263917B/en unknown
- 2017-06-23 US US16/310,606 patent/US11072600B2/en active Active
- 2017-06-23 PL PL17737132.5T patent/PL3475272T3/pl unknown
- 2017-06-23 BR BR112018076821-9A patent/BR112018076821A2/pt unknown
- 2017-06-23 CA CA3029004A patent/CA3029004A1/en active Pending
- 2017-06-23 ES ES17737132T patent/ES2964531T3/es active Active
- 2017-06-23 EP EP17737132.5A patent/EP3475272B1/en active Active
- 2017-06-23 PT PT177371325T patent/PT3475272T/pt unknown
- 2017-06-23 WO PCT/US2017/039119 patent/WO2017223516A1/en unknown
- 2017-06-23 KR KR1020197002267A patent/KR102494294B1/ko active IP Right Grant
-
2018
- 2018-12-17 MX MX2021013641A patent/MX2021013641A/es unknown
- 2018-12-19 ZA ZA2018/08562A patent/ZA201808562B/en unknown
-
2019
- 2019-07-30 US US16/526,620 patent/US10640493B2/en active Active
-
2021
- 2021-07-15 US US17/376,577 patent/US20220402894A1/en active Pending
- 2021-11-26 JP JP2021192564A patent/JP2022037004A/ja active Pending
-
2023
- 2023-01-25 ZA ZA2023/01066A patent/ZA202301066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3029004A1 (en) | 2017-12-28 |
| WO2017223516A1 (en) | 2017-12-28 |
| AU2017280334A1 (en) | 2019-01-17 |
| ES2964531T3 (es) | 2024-04-08 |
| EP3475272A1 (en) | 2019-05-01 |
| US20220402894A1 (en) | 2022-12-22 |
| EP3475272B1 (en) | 2023-09-13 |
| KR20190033534A (ko) | 2019-03-29 |
| BR112018076821A2 (pt) | 2019-04-02 |
| KR102494294B1 (ko) | 2023-01-31 |
| PL3475272T3 (pl) | 2024-04-29 |
| ZA201808562B (en) | 2023-12-20 |
| AU2017280334C1 (en) | 2022-10-20 |
| ZA202301066B (en) | 2024-05-30 |
| US20190352283A1 (en) | 2019-11-21 |
| IL263917A (en) | 2019-02-28 |
| MX2018015893A (es) | 2019-08-01 |
| JP2019522681A (ja) | 2019-08-15 |
| US11072600B2 (en) | 2021-07-27 |
| CN109843874A (zh) | 2019-06-04 |
| PT3475272T (pt) | 2023-12-15 |
| IL263917B (en) | 2022-07-01 |
| AU2017280334B2 (en) | 2021-07-29 |
| US10640493B2 (en) | 2020-05-05 |
| JP2022037004A (ja) | 2022-03-08 |
| US20190337928A1 (en) | 2019-11-07 |
| MX2021013641A (es) | 2022-01-06 |
| CN109843874B (zh) | 2022-05-27 |
| JP7033588B2 (ja) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811393WA (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201908652QA (en) | Pharmaceutical compositions | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |